Search Result "AS703026"
Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Journal: Current Cancer Therapy Reviews
Volume: 8 Issue: 3 Year: 2012 Page: 205-217
Author(s): Lobke G.M. Cremers,Johannes Boonstra
The Therapeutic Promise of Anti-Cancer Drugs Against the Ras/Raf/MEK/ERK Pathway
Ebook: Topics in Anti-Cancer Research
Volume: 2 Year: 2013
Author(s): Erin K. Crane,Kwong-Kwok Wong
Doi: 10.2174/9781608051366113020006
Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer
Journal: Current Cancer Therapy Reviews
Volume: 10 Issue: 1 Year: 2014 Page: 34-38
Author(s): Paul Brittain,S. Gail Eckhardt,Christopher H. Lieu
Molecular Targeted Approaches for Treatment of Pancreatic Cancer
Journal: Current Pharmaceutical Design
Volume: 17 Issue: 2 Year: 2011 Page: 2221-2238
Author(s): Z.Q. Huang, A.K. Saluja, V. Dudeja, S.M. Vickers, D.J. Buchsbaum
In Vitro Sensitivity Profiling of Neuroblastoma Cells Against A Comprehensive Small Molecule Kinase Inhibitor Library to Identify Agents for Future Therapeutic Studies
Journal: Current Cancer Drug Targets
Volume: 17 Issue: 6 Year: 2017 Page: 569-584
Author(s): Anjali Singh,Vanessa Meier-Stephenson,Aarthi Jayanthan,Aru Narendran
Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Journal: Current Drug Targets
Volume: 16 Issue: 1 Year: 2015 Page: 1448-1463
Author(s): Ana Vanessa Nascimento, Hassan Bousbaa, Domingos Ferreira, Bruno Sarmento
Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway
Journal: Current Cancer Drug Targets
Volume: 10 Issue: 8 Year: 2010 Page: 824-833
Author(s): A. J. Weickhardt, N. C. Tebbutt, J. M. Mariadason
Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma
Journal: Recent Patents on Anti-Cancer Drug Discovery
Volume: 14 Issue: 3 Year: 2019 Page: 203-225
Author(s): Debora Basile,Camilla Lisanti,Maria A. Pizzichetta,Paolo Baldo,Giulia Fornasier,Francesco Lo Re,Giuseppe Corona,Fabio Puglisi
Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Journal: Current Cancer Drug Targets
Volume: 11 Issue: 3 Year: 2011 Page: 254-284
Author(s): B. C. Potts, M. X. Albitar, K. C. Anderson, S. Baritaki, C. Berkers, B. Bonavida, J. Chandra, D. Chauhan, J. C. Cusack, W. Fenical, I. M. Ghobrial, M. Groll, P. R. Jensen, K. S. Lam, G. K. Lloyd, W. McBride, D. J. McConkey, C. P. Miller, S. T.C. Neuteboom, Y. Oki, H. Ovaa, F. Pajonk, P. G. Richardson, A. M. Roccaro, C. M. Sloss, M. A. Spear, E. Valashi, A. Younes, M. A. Palladino